Form 4: Director Jaime Vieser Increases Stake in Alaunos

Director Jaime Vieser acquired 6,515 shares of Alaunos Therapeutics common stock in lieu of board fees.

Summary

• Director Jaime Vieser acquired 6,515 shares of common stock on April 29, 2026.
• The shares were issued at a price of $2.59 per share.
• The acquisition was made in lieu of board fees.
• Following the transaction, the director's direct beneficial ownership increased to 38,853 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects insider commitment to the company through equity ownership.

Positives

• Director demonstrates alignment with shareholders by accepting equity in lieu of cash compensation.
• Increased direct ownership stake indicates confidence in the company's future.

Negatives

• None noted.

Risks

• None noted.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Management Comments

• The transaction represents shares of common stock issued in lieu of board fees.

Industry Context

StockSavvy.ai notes that directors accepting equity in lieu of cash fees is a common practice in the biotechnology sector to preserve cash reserves for research and development activities.

Comparison to Industry Standards

• The practice of issuing equity for board compensation is standard among small-cap biotech firms to manage liquidity.

Related Party Transactions

• The reporting person is the Manager of Brushwood LLC, which holds 13,503 shares.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation practices.

Next Steps

• None mentioned.

Key Dates

Keywords

Alaunos Therapeutics, TCRT, Insider Trading, Form 4, Director Compensation